Amendments to the Specification

Please replace the paragraph beginning on page 16, line 8 with the following paragraph:

"Introducing" an amino acid residue at a particular position in a multi-epitope construct, *e.g.*, adjacent, at the C-terminal side, to the C-terminus of the epitope, encompasses configuring multiple epitopes such that a desired residue is at a particular position, *e.g.*, adjacent to the epitope, or such that a deleterious residue is not adjacent to the C-terminus of the epitope. The term also includes inserting an amino acid residue, preferably a preferred or intermediate amino acid residue, at a particular position. An amino acid residue can also be introduced into a sequence by substituting one amino acid residue for another. Preferably, such a substitution is made in accordance with analoging principles set forth, *e.g.*, in co-pending U.S.S.N. 09/260,714 filed 3/1/99, now abandoned and PCT application number PCT/US00/19774.

Please replace the paragraph beginning on page 25, line 7 with the following paragraph:

This application may be relevant to U.S.S.N. 09/189,702 filed 11/10/98 currently pending, which is a CIP of U.S.S.N 08/205,713 filed 3/4/94 now abandoned, which is a CIP of 08/159,184 filed 11/29/93 and now abandoned, which is a CIP of 08/073,205 filed 6/4/93 and now abandoned, which is a CIP of 08/027,146 filed 3/5/93 and now abandoned. The present application is also related to U.S.S.N. 09/226,775 now abandoned, which is a CIP of U.S.S.N. 08/815,396 now abandoned, which claims the

benefit of U.S.S.N. 60/013,113, now abandoned. Furthermore, the present application is related to U.S.S.N. 09/017,735 now abandoned, which is a CIP of abandoned U.S.S.N. 08/589,108; U.S.S.N. 08/753,622 now abandoned, U.S.S.N. 08/822,382 now abandoned, abandoned U.S.S.N. 60/013,980, U.S.S.N. 08/454,033 now abandoned, U.S.S.N. 09/116,424 now abandoned, and U.S.S.N. 08/349,177 now abandoned. The present application is also related to U.S.S.N. 09/017,524 now abandoned, U.S.S.N. 08/821,739 now abandoned, abandoned U.S.S.N. 60/013,833, U.S.S.N. 08/758,409 now abandoned, U.S.S.N. 08/589,107 now abandoned, U.S.S.N. 08/451,913 now abandoned, U.S.S.N. 08/186,266 now U.S. Patent No. 5,662,907, U.S.S.N. 09/116,061 now abandoned, and U.S.S.N. 08/347,610 now abandoned, which is a CIP of U.S.S.N. 08/159,339 now U.S. Patent No. 6,037,135, which is a CIP of abandoned U.S.S.N. 08/103,396, which is a CIP of abandoned U.S.S.N. 08/027,746, which is a CIP of abandoned U.S.S.N. 07/926,666. The present application may also be relevant to U.S.S.N. 09/017,743 now abandoned, U.S.S.N. 08/753,615 now abandoned; U.S.S.N. 08/590,298 now abandoned, U.S.S.N. 09/115,400 now abandoned, and U.S.S.N. 08/452,843 now abandoned, which is a CIP of U.S.S.N. 08/344,824 now abandoned, which is a CIP of abandoned U.S.S.N. 08/278,634. The present application may also be related to provisional U.S.S.N. 60/087,192 now abandoned and U.S.S.N. 09/009,953 now abandoned, which is a CIP of abandoned U.S.S.N. 60/036,713 and abandoned U.S.S.N. 60/037,432. In addition, the present application maybe relevant to U.S.S.N. 09/098,584 now abandoned, and U.S.S.N. 09/239,043 now U.S. Patent No. 6,689,363. The present application may also be relevant to co-pending U.S.S.N. 09/583,200 filed 5/30/00 currently pending, U.S.S.N. 09/260,714 filed 3/1/99 now abandoned, and U.S. Provisional Application 60/239,008, now

abandoned~~"Heteroclitic Analogs And Related Methods", Attorney Docket Number 018623-015810US filed 10/6/00~~. All of the above applications are incorporated herein by reference.

Please replace the paragraph beginning on page 56, line 23 with the following paragraph:

HLA Class I epitopes are generally about 8 to about 13 amino acids in length, in particular 8, 9, 10, or 11 amino acids in length. HLA Class II epitopes are generally about 6 to 25 amino acids in length, in particular about 13 to 21 amino acids in length. An HLA Class I or II epitope can be derived from any desired antigen of interest. The antigen of interest can be a viral antigen, surface receptor, tumor antigen, oncogene, enzyme, or any pathogen, cell or molecule for which an immune response is desired. Epitopes can be selected based on their ability to bind one or multiple HLA alleles. Epitopes that are analogs of naturally occurring sequences can also be included in the multi-epitope constructs described herein. Such analog peptides are described, for example, in PCT applications PCT/US97/03778, PCT/US00/19774, and co-pending U.S.S.N. 09/260,714 filed 3/1/99, now abandoned.